{
    "organizations": [],
    "uuid": "5c2970ea0b40d7f7cba2ec6742274a53828d6e6b",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-allena-pharmaceuticals-initiates-f/brief-allena-pharmaceuticals-initiates-first-phase-3-trial-for-alln-177-in-patients-with-enteric-hyperoxaluria-idUSASB0C8YB",
    "ord_in_thread": 0,
    "title": "BRIEF-Allena Pharmaceuticals Initiates First Phase 3 Trial For ALLN-177 In Patients With Enteric Hyperoxaluria",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 6 (Reuters) - Allena Pharmaceuticals Inc:\n* ALLENA PHARMACEUTICALS INITIATES FIRST PHASE 3 TRIAL FOR ALLN-177 IN PATIENTS WITH ENTERIC HYPEROXALURIA\n* ALLENA PHARMACEUTICALS INC - ‍TOPLINE DATA FROM PHASE 3 TRIAL FOR ALLN-177 EXPECTED IN SECOND HALF OF 2019​\n* ALLENA PHARMACEUTICALS INC - ‍EXPECTS TO INITIATE URIROX-2 IN SECOND HALF OF 2018, CONSISTENT WITH PRIOR GUIDANCE​\n* ALLENA - ‍INITIATION OF URIROX-1 TRIAL FOLLOWS MULTIPLE INTERACTIONS WITH FDA AFTER WHICH FDA CONFIRMED IT HAD NO COMMENTS ON PROTOCOL​\n* ALLENA PHARMACEUTICALS INC - ‍CONTINUES TO ENGAGE WITH FDA TO FINALIZE DESIGN OF URIROX-2​\n* ALLENA - ENGAGING FDA TO DISCUSS PURSUING ACCELERATED APPROVAL PATHWAY FOR PLANNED BLA SUBMISSION FOR ALLN-177 IN PATIENTS WITH ENTERIC HYPEROXALURIA​\n* ALLENA - ‍BELIEVES PHASE 3 PROGRAM, IF SUCCESSFUL, COULD BE ELIGIBLE FOR MAA VIA CONDITIONAL APPROVAL PATHWAY​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-03-06T21:18:00.000+02:00",
    "crawled": "2018-03-07T19:27:12.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "allena",
        "pharmaceutical",
        "inc",
        "allena",
        "pharmaceutical",
        "initiate",
        "first",
        "phase",
        "trial",
        "patient",
        "enteric",
        "hyperoxaluria",
        "allena",
        "pharmaceutical",
        "inc",
        "data",
        "phase",
        "trial",
        "expected",
        "second",
        "half",
        "allena",
        "pharmaceutical",
        "inc",
        "initiate",
        "second",
        "half",
        "consistent",
        "prior",
        "allena",
        "trial",
        "follows",
        "multiple",
        "interaction",
        "fda",
        "fda",
        "confirmed",
        "comment",
        "allena",
        "pharmaceutical",
        "inc",
        "engage",
        "fda",
        "finalize",
        "design",
        "allena",
        "engaging",
        "fda",
        "discus",
        "pursuing",
        "accelerated",
        "approval",
        "pathway",
        "planned",
        "bla",
        "submission",
        "patient",
        "enteric",
        "allena",
        "phase",
        "program",
        "successful",
        "could",
        "eligible",
        "maa",
        "via",
        "conditional",
        "approval",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}